RAFAEL HOLDINGS, INC.
NYSE: RFL (Rafael Holdings, Inc.)
Last update: 11 hours ago1.08
-0.04 (-3.57%)
| Previous Close | 1.12 |
| Volume | 67,240 |
| Price / Sales | 63.51 |
| Price / Book | 0.850 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,633.43% |
| Diluted EPS (TTM) | -0.920 |
| Quarterly Revenue Growth (YOY) | 7.70% |
| Total Debt/Equity (MRQ) | 0.82% |
| Current Ratio (MRQ) | 3.85 |
| Operating Cash Flow (TTM) | -11.44 M |
| Levered Free Cash Flow (TTM) | -6.60 M |
| Return on Assets (TTM) | -9.82% |
| Return on Equity (TTM) | -26.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Real Estate Services (US) | Mixed | Bearish |
| Real Estate Services (Global) | Mixed | Bearish | |
| Stock | Rafael Holdings, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | -0.5 |
| Price Volatility | 0.6 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.42 |
Select this tab to load the latest available analysis.
|
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel. |
|
| Sector | Real Estate |
| Industry | Real Estate Services |
| Investment Style | Small Value |
| % Held by Insiders | 55.72% |
| % Held by Institutions | 9.38% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Founders Fund V Management, Llc | 31 Dec 2025 | 169,451 |
| Ieq Capital, Llc | 30 Jun 2026 | 164,963 |
| Kahn Brothers Group Inc | 30 Jun 2026 | 150,493 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| POLINSKY DAVID | - | 1.31 | -4,245 | -5,561 |
| Aggregate Net Quantity | -4,245 | |||
| Aggregate Net Value ($) | -5,561 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 1.31 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| POLINSKY DAVID | Officer | 25 Oct 2026 | Disposed (-) | 4,245 | 1.31 | 5,561 |
| 5Y Average Dividend Yield | 0.00% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 19 May 2010 | 27 May 2010 | 28 May 2010 | 12.818541 Cash |
| 18 Dec 2009 | 17 Dec 2009 | 31 Dec 2009 | 0.020211 Cash |
| 19 Jun 2009 | 18 Jun 2009 | 30 Jun 2009 | 0.014519 Cash |
| 20 Mar 2009 | 19 Mar 2009 | 31 Mar 2009 | 0.024223 Cash |
| 19 Dec 2008 | 18 Dec 2008 | 31 Dec 2008 | 0.140558 Cash |
| 19 Sep 2008 | 18 Sep 2008 | 30 Sep 2008 | 0.163271 Cash |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |